WaveMan
WaveMan · Company
NPHC · Nutra Pharma Corp
> Search tickers & screens ⌘K
LIVE
← All companies

NPHC Nutra Pharma (NPHC) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001119643
Quote by TradingView
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

What the filings say about NPHC

Activist stakes (13D), 180 days
1 filing
Largest: 100.0% of the class

Nutra Pharma insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for NUTRA PHARMA CORP in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
DEITSCH RIK J
President, CEO
BUY
2022-01-14 SECtraded 2021-11-15
9,000,000
-
-96.0%
DEITSCH RIK J
President, CEO
BUY
2022-01-14 SECtraded 2021-11-15
3,000,000
-
-96.0%
2 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+4.6% year over year
more than 52% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
no short interest reported
The situation: each line is one rule over one dataset
Pure Raw Supplies, LLC disclosed a 5%+ stake (100.0%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch NPHC

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+0.0%12M
+0%+300%+600%+900%2025-102025-122026-022026-042026-062026-082026-10 2026-09-01 · Pure Raw Supplies, LLC filed a 5%+ stake (100.0%)
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NPHC: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in NPHC

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Pure Raw Supplies, LLC
Activist 13D · 2026-09-01
100.0%

NPHC planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

NPHC financials

Revenue growth
+4.6%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$160.8K
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$1.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-0.08x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
n/a
average equity is zero or negative
Return on assets
-731.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$13.3M
market value at close 2026-10-23 on 2026-08-19 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2025-12-31
FCF yield
-150.2%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$257.6K$246.3K$205.6K$438.3K
Gross profit$196.6K$247.3K$396.5K$249.0K
Operating income-$1.5M-$878.4K-$887.0K-$1.9M
Net income-$2.0M-$1.3M-$1.4M$8.2M
EPS (diluted)0.000.000.000.00
Operating cash flow-$1.2M-$424.0K-$550.0K-$762.4K
Cash$12.2K$36.4K$0$0
Long-term debt$136.6K$140.2K$143.7K$8.2M
SEC XBRL, fiscal years, as known on 2026-10-27

NPHC Stock Sonar score 3/7 axes

Find similar shapesCompare

NPHC ranks highest on risk and compliance (99th percentile) and financial health (68th), and lowest on growth (52nd), among Pharma & Biotech peers.

Financial health
68
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.08x · 68 pct, sector of 371
Growth
52
Inputs
  • Revenue growth, YoY+4.6% · 52 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
99
Inputs
  • Short interest, % of floatno short interest or no free float on file
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+0.6% · 99 pct, sector of 511
4 not measured: Profitability, Insider conviction, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

NPHC filings, in plain words

Read the full summary

1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 100.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies